You just read:

Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio

News provided by

Eli Lilly and Company

May 02, 2019, 06:45 ET